UOC
CRSP icon

UBS O'Connor’s CRISPR Therapeutics CRSP Stock Holding History

UBS O'Connor’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$25.5K – 526
2024
Q2 		$25.5K Sell
15,000
-5,000
-25% -$289K ﹤0.01% 471
2024
Q1 		$242K Buy
+20,000
New +$1.43M 0.01% 385

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

UBS O'Connor's CRSP Position: Q1 2019 in Review

UBS O'Connor sold out of CRISPR Therapeutics (CRSP) in Q1 2019, closing a stake of 22,319 shares — an estimated $638K sold.

UBS O'Connor first reported a position in CRSP in Q3 2018 and held it in 2 quarters. The position peaked at $1.33M in Q3 2018. 170 funds tracked by Wall St. Rank hold CRSP as of Q1 2019.

  • UBS O'Connor reported no remaining CRISPR Therapeutics position as of Q1 2019 after selling out during the quarter.
  • UBS O'Connor sold 22,319 CRISPR Therapeutics shares in Q1 2019, an estimated $638K.
  • UBS O'Connor first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 2 quarters.
  • UBS O'Connor's CRISPR Therapeutics position peaked at $1.33M in Q3 2018.
  • 170 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.